LIFECORE BIOMEDICAL INC DE
For the period ended Nov 24, 2024. Filed Jan 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Nov 24, 2024 · Filed Jan 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Revenue
- Revenue
The Company disaggregates its revenue based on how it markets its products and services and reviews results of operations. The following table disaggregates revenues by major product lines and services:
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| November 24, 2024 | November 26, 2023 | November 24, 2024 | November 26, 2023 | |
| CDMO | $25,610 | $23,678 | $45,790 | $45,217 |
| HA manufacturing | 6,954 | 6,472 | 11,479 | 9,455 |
| Total | $32,564 | $30,150 | $57,269 | $54,672 |
The following table disaggregates revenues by the timing of revenue recognition:
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| November 24, 2024 | November 26, 2023 | November 24, 2024 | November 26, 2023 | |
| Revenues recognized over time | $6,122 | $5,827 | $11,998 | $12,208 |
| Revenues recognized at a point in time | 26,442 | 24,323 | 45,271 | 42,464 |
| Total | $32,564 | $30,150 | $57,269 | $54,672 |
During the three months ended November 24, 2024, the Company had revenues concentrations of 10% or greater from three customers, accounting for 40%,18%, and 18%. During the three months ended November 26, 2023, the Company had revenues concentrations of 10% or greater from three customers, accounting for 32%,22%, and 22%.
During the six months ended November 24, 2024, the Company had revenues concentrations of 10% or greater from three customers, accounting for 37%,20% and 14%. During the six months ended November 26, 2023, the Company had revenues concentrations of 10% or greater from three customers, accounting for 31%,22%, and 14%.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.